Back to Search Start Over

Cognitive phenotyping of GBA1-Parkinson's disease: A study on deep brain stimulation outcomes.

Authors :
Fernández-Vidal JM
Aracil-Bolaños I
García-Sánchez C
Campolongo A
Curell M
Rodríguez-Rodriguez R
Aibar-Duran JÁ
Kulisevsky J
Pascual-Sedano B
Source :
Parkinsonism & related disorders [Parkinsonism Relat Disord] 2024 Nov; Vol. 128, pp. 107127. Date of Electronic Publication: 2024 Sep 17.
Publication Year :
2024

Abstract

Background: Heterozygous variants in the glucocerebrosidase (GBA1) gene are the most common genetic risk factor for Parkinson's Disease (PD). GBA1-PD patients exhibit earlier disease onset, severe motor impairment, and heightened cognitive decline. Deep Brain Stimulation (DBS) offers motor improvement for PD patients, but its cognitive effects, particularly in GBA1-PD, are debated.<br />Methods: This study involved 96 PD patients who underwent subthalamic nucleus DBS at Hospital de la Santa Creu i Sant Pau between 2004 and 2023. Clinical and neuropsychological assessments were conducted pre- and post-surgery, focusing on Mattis Dementia Rating Scale (MDRS) and Frontal Systems Behavior Scale (FrSBe). Patients were categorized into GBA1-PD and non-GBA1-PD groups, with non-GBA1-PD further divided into cognitive fast-progressors and slow-progressors.<br />Results: GBA1 variants were present in 13.5 % of patients. GBA1-PD patients showed greater cognitive decline over time, particularly in attention, conceptualization, and memory, compared to non-GBA1-PD. Non-GBA1-PD fast-progressors exhibited significant cognitive deterioration in initiation and conceptualization within the first year post-DBS. Motor outcomes improved similarly across all groups, but slow-progressors showed a greater reduction in Levodopa Equivalent Daily Dose (LEDD).<br />Conclusions: GBA1-PD patients experience more rapid cognitive decline, particularly in posterior-cortical and fronto-striatal functions. Additionally, a subset of non-GBA1-PD patients shows significant early cognitive decline post-DBS, especially in executive functions. Baseline MDRS scores do not predict cognitive outcomes, highlighting the need for further research to refine prognostic tools. Despite cognitive challenges, GBA1-PD patients benefit from DBS in terms of motor outcomes, underscoring the importance of individualized assessments for DBS suitability, regardless of genetic status.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1873-5126
Volume :
128
Database :
MEDLINE
Journal :
Parkinsonism & related disorders
Publication Type :
Academic Journal
Accession number :
39357432
Full Text :
https://doi.org/10.1016/j.parkreldis.2024.107127